A Long-term Efficacy and Safety of NTQ5082 Capsules
ConditionParoxysmal Nocturnal Hemoglobinuria
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorNanjing Chia-tai Tianqing Pharmaceutical
About this trial
NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, open-label study evaluating the long-term efficacy and safety of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria
Eligibility criteria
Qualifiers
1) Age ≥ 18 years, regardless of gender. 2) Subjects who have previously received and completed NTQ5082 study treatment and, as determined by the investigator, have benefited from treatment and are likely to benefit from continued NTQ5082 treatment, or subjects in the control group receiving eculizumab.
Disqualifiers
1) Previous history of bone marrow/hematopoietic stem cell or solid organ transplant (e.g., heart, lung, kidney, liver).
Trial design
Treatments tested in this trial
- NTQ5082 capsules 200 mg
Treatment groups
78 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov